117 related articles for article (PubMed ID: 35470542)
1. Male breast cancer: a Singapore perspective.
Lim JSH; Sim Y; Ngeow J; Yuen J; Tan VKM; Tan BKT; Yong WS; Wong CY; Lim SZ; Hamzah JLB; Tan SY; Wong FY; Madhukumar P
ANZ J Surg; 2022 Jun; 92(6):1440-1446. PubMed ID: 35470542
[TBL] [Abstract][Full Text] [Related]
2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
3. [Lobular invasive breast cancer prognostic factors: About 940 patients].
Jauffret C; Houvenaeghel G; Classe JM; Garbay JR; Giard S; Charitansky H; Cohen M; Bélichard C; Faure C; Darai É; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Goncalves A; Lambaudie É
Gynecol Obstet Fertil; 2015 Nov; 43(11):712-7. PubMed ID: 26482833
[TBL] [Abstract][Full Text] [Related]
4. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
5. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
[TBL] [Abstract][Full Text] [Related]
6. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
[TBL] [Abstract][Full Text] [Related]
7. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
8. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
9. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.
Mansel RE; Fallowfield L; Kissin M; Goyal A; Newcombe RG; Dixon JM; Yiangou C; Horgan K; Bundred N; Monypenny I; England D; Sibbering M; Abdullah TI; Barr L; Chetty U; Sinnett DH; Fleissig A; Clarke D; Ell PJ
J Natl Cancer Inst; 2006 May; 98(9):599-609. PubMed ID: 16670385
[TBL] [Abstract][Full Text] [Related]
10. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy.
Lim SZ; Kusumawidjaja G; Mohd Ishak HM; Tan BKT; Tan SY; Hamzah JL; Madhukumar P; Yong WS; Wong CY; Sim Y; Lim GH; Lim SH; Tan SM; Wong FY; Tan VKM
Breast Cancer Res Treat; 2021 Oct; 189(3):837-843. PubMed ID: 34342766
[TBL] [Abstract][Full Text] [Related]
12. Axillary Lymph Node Dissection Does Not Improve Post-mastectomy Overall or Disease-Free Survival among Breast Cancer Patients with 1-3 Positive Nodes.
Joo JH; Kim SS; Son BH; Ahn SD; Jung JH; Choi EK; Ahn SH; Lee JW; Kim HJ; Ko BS
Cancer Res Treat; 2019 Jul; 51(3):1011-1021. PubMed ID: 30322228
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.
FitzSullivan E; Bassett RL; Kuerer HM; Mittendorf EA; Yi M; Hunt KK; Babiera GV; Caudle AS; Black DM; Bedrosian I; Reyna C; Teshome M; Meric-Bernstam F; Hwang R
Ann Surg Oncol; 2017 Mar; 24(3):652-659. PubMed ID: 27822630
[TBL] [Abstract][Full Text] [Related]
14. The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance.
Youssef MMG; Cameron D; Pucher PH; Olsen S; Ferguson D
Breast; 2016 Dec; 30():101-104. PubMed ID: 27668857
[TBL] [Abstract][Full Text] [Related]
15. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
[TBL] [Abstract][Full Text] [Related]
16. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
18. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
20. [Incidence of axillary recurrence after a negative sentinel lymph node result in early stages of breast cancer: a 5-year follow-up].
Ruano Pérez R; Ramos Boyero M; García-Talavera Fernández JR; Ramos Grande T; González-Orús JM; Gómez-Caminero López F; García Macias MC; Martín de Arriba A
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):173-7. PubMed ID: 23067685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
